An observational study in Intraductal Papillary Mucinous Neoplasms, Pancreatic Cystic Neoplasms and IPMN, sponsored by IRCCS San Raffaele. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Pancreatic Neoplasms by IRCCS San Raffaele — 9 open to participants now, 10 under way, none of them phase 3. Pancreatic Neoplasms · IRCCS San Raffaele.
Among the 23 studies in Pancreatic Neoplasms by IRCCS San Raffaele, this one is the 7th largest by enrollment of the 10 observational ones that give a count, is the only one that started in 2015, is one of 10 observational ones, and was the 21st registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →9 of the 23 studies in Pancreatic Neoplasms by IRCCS San Raffaele are open now, in 4 countries. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in France, Italy, Portugal and 1 more country
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 1
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is close to the median of 200 across 743 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 80 across the 13 interventional studies, 415 across the 10 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele is the lead sponsor of 455 studies on the registry; 235 are open to participants now.
7 of the studies in Pancreatic Neoplasms by IRCCS San Raffaele that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06071507IRCCS San RaffaeleManagement of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy | 2026-12 |
| NCT06069297IRCCS San RaffaelePrehabilitation in Pancreatic Surgery | 2026-12-16 |
| NCT07095621IRCCS San RaffaeleFeasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy | 2026-12-31 |
| NCT05714124IRCCS San RaffaeleLiver Embolization Approaches for Tumor Management | 2026-12-31 |
| NCT05714111IRCCS San RaffaeleRadiology Registry on Pancreatic Malignancies | 2027-03-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 23 studies in Pancreatic Neoplasms by IRCCS San Raffaele, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intraductal papillary mucinous neoplasms (IPMNs) are among the most clinically relevant pancreatic cystic lesions because of their potential for malignant transformation into high-grade dysplasia or invasive carcinoma. Accurate preoperative risk stratification is essential to identify patients who may benefit from surgical resection while avoiding unnecessary surgery in those with low-grade disease.
Endoscopic ultrasound (EUS) plays a central role in the evaluation of IPMNs because it allows detailed assessment of ductal and cystic features associated with malignancy, including mural nodules, main pancreatic duct abnormalities, wall thickening, contrast enhancement, and elastography patterns. However, the combined predictive value of these features has not been fully standardized.
The IMAGE study is a single-center retrospective study designed to develop and validate a machine learning-based model integrating comprehensive EUS features to predict the presence of high-grade dysplasia or invasive carcinoma in patients with surgically resected IPMNs. The study includes adult patients who underwent preoperative EUS at a tertiary referral center and had a final histological diagnosis of IPMN after surgery.
The primary objective is to assess the diagnostic performance of the IMAGE model for predicting high-grade dysplasia or invasive carcinoma. Secondary objectives include evaluation of the diagnostic contribution of individual EUS feature domains and assessment of agreement between preoperative EUS classification and final histological diagnosis.
Intraductal papillary mucinous neoplasms (IPMNs) are increasingly recognized pancreatic cystic lesions characterized by a wide spectrum of biological behavior, ranging from low-grade dysplasia to high-grade dysplasia and invasive carcinoma. Because pancreatic surgery is associated with significant morbidity and mortality, accurate preoperative risk stratification is essential to identify patients who may benefit from resection while avoiding unnecessary surgery in those with low-risk disease.
Endoscopic ultrasound (EUS) represents one of the most informative imaging modalities for the evaluation of IPMNs, allowing detailed characterization of both ductal and cystic features associated with malignant transformation. These include main pancreatic duct dilation, duct wall abnormalities, intraductal nodules, cyst size and wall thickening, mural nodules, contrast-enhancement patterns, and elastographic characteristics. In addition, EUS may allow tissue acquisition when clinically indicated. However, the interpretation of these multiple features is complex, and their combined predictive value is not fully standardized in clinical practice.
The IMAGE study (IPMN Malignancy Assessment through Grading by Endoscopic ultrasound) is a single-center retrospective study based on a prospectively maintained database from a tertiary referral center for pancreatic diseases. The study includes consecutive adult patients who underwent surgical resection for IPMN between 2015 and 2023 and who had preoperative EUS performed at the study center.
Patients are eligible if they are older than 18 years, underwent preoperative EUS at the study center, and had a final histological diagnosis of IPMN after surgery. Patients are excluded if EUS was performed at another institution, if the interval between EUS and surgery exceeded six months, or if preoperative EUS showed suspicion of infiltrating pancreatic carcinoma with a macroscopic infiltrative solid component.
For each patient, demographic, EUS, cytological (when available), and histopathological data are collected. Due to the retrospective design and variability in original reports, stored EUS images and videos are independently re-reviewed by experienced endosonographers blinded to the final histological diagnosis. Morphological, contrast-enhanced, elastographic, and cytological features are standardized by consensus, with adjudication by a third blinded reviewer in case of disagreement.
EUS variables include both duct-related and cyst-related features. Duct-related variables comprise main pancreatic duct dilation, duct wall thickening, intraductal echogenicity, hypoechogenicity of the duct wall, presence and size of pancreatic duct nodules, contrast enhancement of duct nodules, and elastographic patterns. Cyst-related variables include cyst size, cyst wall thickening, contrast enhancement of the cyst wall, presence and size of mural nodules, contrast enhancement of mural nodules, and elastographic patterns.
The primary aim of the study is to develop and validate a machine learning-based model integrating comprehensive EUS features to predict the presence of high-grade dysplasia or invasive carcinoma. The model, termed IMAGE, generates a continuous risk score representing the probability of high-grade dysplasia or invasive carcinoma based on EUS-derived variables.
The dataset is divided into training and testing cohorts using a predefined split, ensuring balanced distribution of key clinical variables. The testing cohort is not used during model development. Model performance is evaluated using discrimination metrics, including area under the receiver operating characteristic curve, as well as sensitivity and specificity at a predefined positivity threshold.
Secondary objectives include evaluating the diagnostic contribution of individual EUS feature domains (ductal, cystic, and non-ductal/non-cystic features) and assessing whether a unified model integrating all EUS variables provides incremental diagnostic performance compared with models based on isolated feature domains. Additional analyses include assessment of the agreement between preoperative EUS classification and final histological diagnosis, including IPMN subtype classification and cytology-histology concordance when tissue acquisition is available.
Adult patients with histologically confirmed intraductal papillary mucinous neoplasms (IPMNs) who underwent surgical resection at a tertiary referral center between 2015 and 2023 and had preoperative endoscopic ultrasound (EUS) evaluation available for analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients with histologically confirmed intraductal papillary mucinous neoplasms (IPMNs) who underwent surgical resection between 2015 and 2023 and had preoperative endoscopic ultrasound (EUS) performed at a tertiary referral center.
Other: Endoscopic Ultrasound (EUS) Assessment
Observational evaluation of endoscopic ultrasound (EUS) features, including ductal and cystic characteristics, contrast-enhanced imaging, elastography, and tissue acquisition when clinically indicated, as part of routine clinical practice. No study-specific intervention is performed.
Area Under the ROC Curve (AUROC) of the IMAGE Model for Predicting High-Grade Dysplasia or Invasive Carcinoma
Discrimination of the IMAGE machine learning model, which generates a continuous risk score from EUS-derived variables, for predicting high-grade dysplasia or invasive carcinoma in the testing cohort, using final surgical histology as the reference standard. AUROC ranges from 0 to 1, where 0.5 indicates no discrimination and 1 indicates perfect discrimination.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
Sensitivity of the IMAGE Model for Predicting High-Grade Dysplasia or Invasive Carcinoma
Percentage of participants with high-grade dysplasia or invasive carcinoma at final histology who are classified as positive by the IMAGE model at a predefined positivity threshold, in the testing cohort.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
Specificity of the IMAGE Model for Predicting High-Grade Dysplasia or Invasive Carcinoma
ercentage of participants without high-grade dysplasia or invasive carcinoma at final histology who are classified as negative by the IMAGE model at the predefined positivity threshold, in the testing cohort.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
AUROC of Single-Domain EUS Models for Predicting High-Grade Dysplasia or Invasive Carcinoma
AUROC of separate machine learning models, each built on a single EUS feature domain (ductal features, cystic features, non-ductal/non-cystic features), for predicting high-grade dysplasia or invasive carcinoma, using final surgical histology as the reference standard. One value is reported for each domain. AUROC ranges from 0 to 1, where 0.5 indicates no discrimination and 1 indicates perfect discrimination.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
Difference in AUROC Between the Integrated IMAGE Model and Single-Domain EUS Models
Difference in AUROC between the integrated IMAGE model (all EUS features combined) and each single-domain model (ductal, cystic, non-ductal/non-cystic) for predicting high-grade dysplasia or invasive carcinoma. Positive values indicate better discrimination by the integrated model.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
Percentage of Participants With Concordant IPMN Morphological Subtype Between Preoperative EUS and Final Histology
Percentage of participants in whom the IPMN morphological subtype assigned at preoperative EUS (main-duct, branch-duct, or mixed-type) matches the subtype at final histological diagnosis.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
Percentage of Participants With Concordant Cytology and Final Histology
Among participants who underwent EUS-guided tissue acquisition, percentage in whom the cytological diagnosis is concordant with the final histological diagnosis.
Time frame: At time of surgery (histological diagnosis within 6 months from EUS)
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in Dec 2025, 128 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.